Early Imaging Detection of CV Injury after Cancer

癌症后心血管损伤的早期影像检测

基本信息

批准号：
8478069
负责人：
William Gregory Hundley
金额：
$ 47.89万
依托单位：
WAKE FOREST UNIVERSITY HEALTH SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-06-01 至 2017-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8478069
关键词：
10 year old Accounting Adjuvant Adult Age Anthracyclines Aorta Asians Atherosclerosis Breast Cancer Treatment Cancer Survivor Cardiac Cardiac Death Cardiovascular Diseases Cardiovascular system Case Study Caucasians Caucasoid Race Chemotherapy-Oncologic Procedure Child Clinical Clinical Research Collaborations Comorbidity Computer software Congenital Heart Defects Congestive Heart Failure Coronary Arteriosclerosis Data Data Element Data Quality Detection Development Diabetes Mellitus Disease EFRAC Early Diagnosis Etiology Event Exposure to Fibrosis Funding Future Gender Guidelines Health Sciences Heart Hispanics Hypertension Image Individual Injury Institution Investigation Left Left Ventricular Function Lymphoma Magnetic Resonance Imaging Malignant Neoplasms Matched Group Measures Medical center Methodology Metric Monitor Morbidity - disease rate Myocardial Myocardial Infarction NIH Program Announcements Participant Patients Persons Physiologic pulse Population Population Projection Procedures Race Relative (related person)Reporting Research Research Personnel Risk Risk Factors Scientist Secondary to Series Signal Transduction Smoking Solutions Specific qualifier value Standardization Stroke Survivors Technology Testing Therapeutic Intervention Time Translating Translations Treatment Protocols Universities Validation Ventricular aged base cardiovascular imaging cardiovascular injury cardiovascular risk factor case control chemotherapy cohort cost cost effective design forest imaging modality improved in vivo innovation leukemia/lymphoma malignant breast neoplasm mortality neglect new technology outcome forecast population based pre-clinical pre-clinical therapy prevent prototype systems research

项目摘要

DESCRIPTION (provided by applicant): Cardiovascular (CV) injury leading to myocardial infarction (MI), cardiac death, stroke, and congestive heart failure (CHF) is a major impediment to the curative use of anthracycline-based chemotherapy for the treatment of adjuvant breast cancer, leukemia, and lymphoma. No clinically acceptable alternatives exist for children or adults that require this therapy. The assembled academic-industrial team will develop and optimize a cost-effective, automated, reproducible hardware/software platform that acquires, analyzes, and reports subclinical and clinical CV injury, identifies the mechanisms of this injury and forecasts CV event risks. This important information can be utilized for preclinical treatment protocols that, when administered to other high CV risk populations, reduce the rates of adverse CV events. This well-designed and powered pivotal clinical study to validate these technologies will: " Collect within person longitudinal results before anthracycline exposure and at 3 and 24 months after exposure to determine if short-term results predict long-term subclinical disease that portends an adverse prognosis~ " Determine the efficacy of this new platform in children and adults aged 10 to 80 years~ " Derive population (age, gender, race, and cardiac risk factor-matched) predictive metrics for the platform compared against 6,000 individuals without known coronary artery disease from the existing Multi-Ethnic Study of Atherosclerosis (MESA)~ " Standardize the automated platform to enable medical centers throughout the world with little MRI expertise to reliably and reproducibly perform the studies. This platform innovation is based on strong NCI funded preliminary data and provides a highly significant cost effective solution for a previously unsolved clinical problem that noninvasively defines early CV risk and enables targeted therapeutic interventions to dramatically reduce these risks. Reducing CV events in cancer survivors will reduce overall morbidity in patients with cancer and improve cancer-related survival.

描述（由申请人提供）：导致心肌梗塞（MI），心脏死亡，中风和充血性心力衰竭（CHF）的心血管（CV）损伤是治疗基于蒽环类药物治疗辅助乳腺癌，白血病和淋巴瘤的主要障碍。对于需要这种疗法的儿童或成人，没有临床上可接受的替代方法。组装的学术工业团队将开发和优化一个具有成本效益，自动化，可重复的硬件/软件平台，该平台获取，分析和报告亚临床和临床CV伤害，并确定了这种伤害的机制，并预测了CV事件风险。这些重要信息可以用于临床前治疗协议时，该协议降低了不良简历事件的速度。 This well-designed and powered pivotal clinical study to validate these technologies will: " Collect within person longitudinal results before anthracycline exposure and at 3 and 24 months after exposure to determine if short-term results predict long-term subclinical disease that portends an adverse prognosis~ " Determine the efficacy of this new platform in children and adults aged 10 to 80 years~ " Derive population (age, gender, race, and cardiac risk该平台的因素匹配度指标与现有的动脉粥样硬化多民族研究（MESA）的6,000名没有已知冠状动脉疾病的个体相比，“标准化自动化平台可以使全世界的医疗中心几乎没有MRI专业知识来可靠地可靠和可重复进行研究。该平台创新基于强大的NCI资助初步数据，并为以前未解决的临床问题提供了非常重要的成本效益解决方案，该问题非侵入性地定义了早期的简历风险，并实现了有针对性的治疗干预措施，以大大降低这些风险。减少癌症幸存者中的简历事件将降低患者的总体发病率癌症并改善与癌症相关的生存。